Elevated CD47 expression on some cancer cells protects tumors from innate immune surveillance and limits adaptive antitumor immunity via inhibitory SIRPα signaling in antigen-presenting cells. CD47 also mediates inhibitory thrombospondin-1 signaling in vascular cells, T cells and NK cells; blocking inhibitory CD47 signaling on cytotoxic T ...

2023年3月7日 · Among all phagocytosis checkpoints, CD47 is the most thoroughly studied and has emerged as a rising star among targets for cancer treatment. CD47-targeting antibodies and inhibitors have been...

2022年6月13日 · CD47 performs a vital function in cancer therapy by binding to different SIRPα, thrombospondin 1, and integrin. However, its role in tumor immunity and its correlation with prognosis among many...

Cluster of differentiation 47 (CD47), a protein that normally prevents healthy cells from being attacked by immune cells, is often overexpressed on cancer cells. This makes CD47 a prime target for immunotherapy.

Here, we review the role of CD47 in the maintenance of immune system homeostasis. We also depict three emerging CD47-targeting strategies for cancer therapy, including the use of mimicry peptides, antibodies, and gene silencing strategies. Among these approaches, the most advanced one is the use of …

2024年9月1日 · CD47 is highly expressed in cancers to prevent phagocytosis by phagocytes. Targeting CD47 has been verified as a promising therapeutic strategy in cancer immunotherapy. Antibodies and small molecules targeting CD47 exhibited both safety and efficacy in clinical trials.

In this review we highlight the role of tumor immune evasion through the inhibition of phagocytosis, specifically through the CD47-SIRPα pathway, and discuss how targeting this pathway might lead to more effective cancer immunotherapies.

2019年8月14日 · Ample studies have shown that various types of cancer express high levels of CD47 to escape from the immune system. Based on this observation, CD47 is currently considered as a prominent target in cancer therapy. Here, we review the role of CD47 in the maintenance of immune system homeostasis.

4 天之前 · SiGSTK1-LNPs enhances the phagocytosis effect of anti-CD47 antibody in different cancer cells. (A&B) Cancer cells were treated with siGSTK1-LNPs or siCTRL-LNPs for 24 h, followed by incubation in normal medium for another 24 h. The transfection efficiency was detected with Incucyte S3 machine and western blot.

2025年3月21日 · 而最新发表在《Nature Cancer》的研究中，MD安德森癌症中心团队开发的新型抗体毒素偶联物（CD47-LLO），成功通过激活先天性免疫，重塑了肿瘤微环境，甚至能协同现有疗法。这项成果为未来的癌症治疗带来了全新可能。